

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10767,476	
			Filing Date	01/28/2004	
			First Named Inventor	Stuelpnagel et al.	
			Art Unit	1639	
			Examiner Name	Steele, Amber D.	
Sheet	1	of	2	Attorney Docket Number	01-00008

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Document Number/Kind Code‡	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	4,349,510	09/14/1982	Kolehmainen et al.	
	2	4,879,097	11/07/1989	Whitehead et al.	
	3	4,922,092	05/01/1990	Rushbrooke et al.	
	4	5,618,701	04/08/1997	Landegren	
	5	5,682,232	10/28/1997	Tajima et al.	
	6	5,784,152	07/21/1998	Heffelfinger et al.	
	7	5,800,922	09/01/1998	Fodor et al.	
	8	5,878,946	03/02/1999	Burbaum et al.	
	9	6,083,763	07/04/2000	Balch	
	10	6,191,852	02/20/2001	Paiffhausen et al.	
	11	6,327,410	12/04/2001	Walt et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Foreign Patent Document/ Country Code-Number-Kind Code‡	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
	12	EP 0 269 764	06/08/1988	Molecular Biosystems, Inc.		
	13	WO 89/11101	11/16/1989	Dynal A.S.		
	14	EP 0 478 319	04/01/1992	Kabushiki Kaisha Toshiba		
	15	WO 93/02360	02/07/1993	Trans-Med Biotech, Inc.		
	16	WO 96/03212	02/06/1996	Sydney Brenner		
	17	WO 97/14028	04/17/1997	Luminex Corp.		
	18	WO 99/05320	02/04/1999	Rapigene, Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this file with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Error Office that issued the document, by the two-letter code (WFO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WFO Standard ST, 16 if possible. ‡ Applicant to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is submitted in less than 2 hours in complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/767,476	
			Filing Date	01/28/2004	
			First Named Inventor	Stuelpnagel et al.	
			Art Unit	1639	
			Examiner Name	Steele, Amber D.	
Sheet	2	of	2	Attorney Docket Number	01-00008

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T‡
	19	DRMANAC, R. et al., "Sequencing by Hybridization," Automated DNA Sequencing and Analysis, ed. M. Adams, C. Fields and J. Venter (1994).	
	20	ILLUMINA INC., "Emerging," Windhover's In Vivo, The Business and Medicine Report, 1 - 2 (1998).	
	21	ILLUMINA INC., Slides presented by Illumina at Cambridge Healthtech Institute's Implications of Human Genetic Variation - SNP's, Polymorphisms, Diseases & Treatment. November 18-19, 1998, Waltham, Massachusetts.	
	22	POPE, E., "Fiber Optic Chemical Microsensors Employing Optically Active Silica Microspheres," SPIE Proc., 2388:245 - 256 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 42 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450